Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNI-free versus low-dose CNI immunosuppression after de novo heart transplantation
2007-002671-14Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus, mycophenolate sodium and cyclosporine in heart transplantation (2 arms), sponsored by Novartis. Primary endpoint: Glomerular filtration rate at Month 18. Started Dec 2007; status: completed.
02
Drugs
everolimusmycophenolate sodiumcyclosporine
03
Conditions
heart transplantation
Beyond the preview
Go deeper on 2007-002671-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002671-14.